SAGE PRO

Home / Research / Optiemus Infracom Limited

SAGE PRO · ORIGINAL EQUITY RESEARCH

Optiemus Infracom Limited — Q2 FY27 Results Analysis

Sales have scaled dramatically, but margins lag

Published · Quarter Q2 FY27 · OPTIEMUS

COMPANY-SPECIFIC GRAPHICAL SUMMARY

What the reported figures reveal

CHART 1

Consolidated revenue

Q2 FY26₹418.27 crore
Q1 FY27₹882.99 crore
Q2 FY27₹983.17 crore

Optiemus revised issuer investor presentation dated 2026-11-06, Q2 FY27, consolidated financial summary

CHART 2

EBITDA margin

Q2 FY268.04%
Q1 FY273.44%
Q2 FY274.08%

Optiemus revised issuer investor presentation dated 2026-11-06, Q2 FY27, consolidated financial summary

CHART 3

EBITDA

Q2 FY26₹33.62 crore
Q1 FY27₹30.41 crore
Q2 FY27₹40.14 crore

Optiemus revised issuer investor presentation dated 2026-11-06, Q2 FY27, consolidated financial summary

CHART 4

PAT

Q2 FY26₹16.78 crore
Q1 FY27₹21.18 crore
Q2 FY27₹21.01 crore

Optiemus revised issuer investor presentation dated 2026-11-06, Q2 FY27, consolidated financial summary

ORIGINAL RESEARCH INSIGHTS

Investment findings and watch points

RESEARCH INSIGHT

Sales have scaled dramatically, but margins lag

Revenue more than doubled YoY, while reported margin nearly halved.

Watch: Track cash profit before re-rating the growth

RESEARCH INSIGHT

Profit growth is much slower than sales growth

Q2 EBITDA gained 19% YoY despite revenue gaining 135%.

Watch: Compare the next reported earnings with sales

RESEARCH INSIGHT

FY28 and FY29 require major new businesses to scale

These are issuer objectives, not achieved results or analyst forecasts.

Watch: Require actual profitable utilisation before assuming targets

RESEARCH INSIGHT

Declining PAT conversion and incubation costs matter

Reported profitability reflects costs from developing new business lines.

Watch: Evaluate reported numbers before excluding investment drag

FULL PUBLISHED RESEARCH

Earnings and management commentary analysis

NSE OPTIEMUS · BSE 530135 · 20 November 2026 · Consolidated financials

Investment decision dashboard

WATCH: unusually strong revenue growth, but operating margins have yet to recover proportionately. Optiemus is transforming from distribution and telecom into a diversified electronics-manufacturing platform. Its reported Q2 FY27 revenue rose 135% year on year to ₹983.17 crore while EBITDA increased only 19% to ₹40.14 crore and PAT increased 25% to ₹21.01 crore. The central question is whether recent output growth can become sustained cash profits after the next investment cycle.

The company is building three distinct options beyond its smartphone electronics-manufacturing-services business: the KAVACH screen-protector consumer category, a CMF/Nothing brand partnership, and Corning-linked cover-glass manufacturing. Its drone subsidiary offers a longer-dated option. These initiatives should not all be valued as mature businesses today.

Management targets approximately ₹3,600 crore revenue in FY27, ₹6,500 crore in FY28 and ₹8,500 crore in FY29. Targets are not contracted sales, and this research does not treat them as Sage PRO forecasts. The investment case would improve materially if manufacturing EBITDA margins rise, new ventures win paying customers, and cash conversion keeps up with revenue growth.

1. Core business and industry economics

Optiemus manufactures electronic devices and participates in device distribution and product ecosystems. Smartphone EMS is the current scale engine. The company reports that smartphone manufacturing has delivered successive quarters above ₹500 crore; recently commissioned Noida Unit 3 and growing non-mobile partnerships support its top line. Contract manufacturing can grow extremely rapidly as programmes ramp, but it typically carries lower margins than branded electronics or proprietary components. Customers may also possess considerable bargaining power.

The core economic tests are customer concentration, contribution margin, repeat manufacturing programmes, inventory cycles, receivable collection and capital intensity. A doubling of EMS revenue has limited value if equipment and working capital need to double while incremental operating profit remains thin. For Optiemus, distinguishing smartphone assembly from higher-margin or differentiated categories is important.

KAVACH is a branded screen-protector offering that uses the company's manufacturing and distribution reach. Management plans 25 million monthly screen-protector units of capacity, consisting of 5 million brownfield units targeted around January/February 2027 and another 20 million greenfield units at a leased facility. Estimated project capex is approximately ₹250–300 crore. The stated catalyst is a BIS-related compliance change due in April 2027 that could support local manufacturing. Investors should measure customer orders, capacity utilisation, actual sell-through, gross margin and returns on capital; merely announcing capacity is not proof of profitable demand.

The planned CMF/Nothing joint venture seeks to move the company beyond assembling devices into brand participation. The issuer presentation says definitive agreements and regulatory steps remain in progress. It is therefore a potential future source of value rather than established recurring profit. Brand ownership adds marketing, distribution, warranty and inventory obligations along with any gross-margin benefits.

The 70:30 BIG Tech joint venture with Corning International has a finished cover-glass plant in Tamil Nadu. The company reports ongoing customer site visits, technical trials and OEM audits, with onboarding envisaged over three to four quarters. Cover glass could be harder to replicate than basic assembly, but qualification, yield, volume, pricing and plant depreciation need to be tested before assigning strong earnings forecasts. The wholly owned drone subsidiary is building agriculture and defence applications, including service-based opportunities; this is speculative option value until meaningful contracts and collections are disclosed.

2. Q2 FY27 result: exceptional volume growth, modest profit leverage

Consolidated metricQ2 FY26Q1 FY27Q2 FY27
Revenue (₹ crore)418.27882.99983.17
EBITDA (₹ crore)33.6230.4140.14
EBITDA margin8.04%3.44%4.08%
Profit before tax (₹ crore)24.9028.2428.90
Profit after tax (₹ crore)16.7821.1821.01
PAT margin4.01%2.40%2.14%

Revenue was 135% higher year on year and 11% higher sequentially. EBITDA increased 19% year on year and 32% sequentially. Yet EBITDA margin of 4.08% remained 396 basis points below Q2 FY26. PAT increased 25% year on year but slipped slightly quarter on quarter. PAT margin of 2.14% was around 187 basis points below the prior year. These are economic warning signs to analyse, not grounds on their own to reject the company: the manufacturing mix and new-facility ramp may produce a temporary margin trough, but investors need proof.

Management attributes the sequential EBITDA improvement to mix and Noida Unit 3 operating leverage. Other income declined from ₹10.91 crore in Q1 to ₹3.06 crore in Q2; depreciation rose from ₹6.63 crore to ₹8.67 crore. This partially explains why the improvement in EBITDA did not translate into comparable sequential PAT growth.

On a consolidated H1 FY27 basis, revenue reached approximately ₹1,866.16 crore versus ₹853.63 crore one year earlier, EBITDA ₹70.55 crore versus ₹60.37 crore, and PAT ₹42.19 crore versus ₹31.31 crore. Thus the first-half sales expansion exceeded earnings expansion by a wide margin.

The company identifies roughly ₹3.57 crore EBITDA drag and ₹4.11 crore PAT drag from incubating drones and cover glass in Q2. Adding these costs back gives issuer-adjusted core EBITDA of ₹43.71 crore and PAT of ₹25.12 crore; the adjusted EBITDA margin is 4.45%. These numbers help show the core manufacturing picture, but early-stage business costs still belong to shareholders and should not be permanently excluded from valuations.

3. Guidance bridge: how credible is the next step?

Management maintains about ₹3,600 crore FY27 revenue guidance. H1 FY27 already contributed ₹1,866 crore. The target implies approximately ₹1,734 crore for H2, averaging ₹867 crore per quarter, below Q2 actual revenue. On pure revenue arithmetic, near-term guidance is therefore feasible if existing programmes continue. Achieving the number and earning attractive returns on it are different questions.

The approximately ₹6,500 crore FY28 and ₹8,500 crore FY29 targets involve a significantly more ambitious growth phase, attributed to screen protectors and EMS scale. Their achievement depends on functioning plants, customer adoption, effective route-to-market and profitability. Revenue should be measured against EBITDA per unit of sales, incremental working capital and cash generated after capex.

Management has also outlined financing of approximately ₹200 crore through new securities with the balance of project funding from borrowings and internal accruals. This is a material shareholder-economics issue. Investors need the final issuance price, instruments, fully diluted shares, promoter participation, debt terms and resulting interest expense. An increase in promoter ownership may align incentives, but favourable capital allocation cannot be assumed without the transaction documents.

4. Differentiation and potential competitive advantage

The strongest possible moat is the combination of a scaled manufacturing base, distribution reach, localisation and technical capability. EMS programmes offer scale and customer relationships; screen protectors potentially add own-brand economics; the Corning venture could introduce materials expertise and higher switching costs. Each link has different proof requirements. A manufacturing plant with one large customer is not equivalent to a diversified, high-margin technology franchise.

The coming BIS transition is an opportunity as well as a risk. If localisation reduces imported competition and Optiemus launches at scale ahead of rivals, branded screen protectors could be accretive. If competitors add local capacity quickly, supply can outrun demand and dilute profitability. The business should eventually be evaluated on actual channel shipments, returns, claims and distributor economics.

5. Principal downside risks

Profit dilution: A large smartphone EMS mix can keep operating margins thin even while turnover is growing strongly. A repeat of 135% revenue growth with only modest EBITDA growth would not support aggressive premium valuation.

Project execution: Screen protectors, CMF, cover glass and drones are being developed concurrently. Delays in qualification, launch or equipment commissioning could postpone returns and absorb management attention.

Cash flow and funding: Rapid growth can inflate receivables and inventory. Large capex and financing needs could rise ahead of revenue realisation. Review half-year and annual cash-flow statements and capital commitments alongside P&L.

Share dilution and leverage: New equity and debt finance growth but potentially reduce earnings per existing share or raise fixed financial costs. Assess every subsequent earnings estimate on a diluted basis.

Customer and regulatory concentration: EMS is influenced by individual customer programmes and product refreshes; the screen-protector opportunity is partly linked to government standards and policy implementation. Changes in either can alter returns quickly.

R&D business uncertainty: The cover-glass and drone businesses consume money before revenue maturity. Treat these as investments with uncertain payback, not automatically as margins to be added back forever.

6. Valuation and 3–6 month investment action plan

Current stance: WATCH / AWAIT EVIDENCE OF PROFIT CONVERSION. This publication does not assert a live market price, fully diluted market capitalisation, EV/EBITDA, peer premium or target price because the current share count, financing structure and up-to-date price-based valuation have not been reconciled for this edition. A sales multiple alone would be misleading with margins near 4%.

The bull thesis is continued EMS volume, an orderly screen-protector ramp, successful OEM qualification in cover glass, higher recurring EBITDA margins and funding on reasonable shareholder terms. The base thesis is continued sales expansion with slower improvement in core profitability and material investment expenditure. The bear thesis is a low-margin EMS growth cycle with delayed diversification, high working-capital requirements and dilution or increased leverage. These are economic scenarios, not numerical return predictions.

For the next 3–6 months, the key action is to follow margin expansion and cash conversion rather than chase guidance revisions. A more constructive research position requires a stronger reported EBITDA margin, measured business conversion of new verticals, and consistent consolidated cash generation. A weaker position would follow continued margin deterioration, delayed customer onboarding and additional funding needs without visible cash profits.

7. Specific next-quarter monitoring

  1. Consolidated EBITDA margin: compare to Q2's 4.08% and the 8.04% historical comparator. Improvement should come from reported operations, not only adjusting away investment costs.
  2. Revenue per division: obtain smartphone EMS versus non-mobile, consumer products and cover glass; avoid treating a new order announcement as recognised sales.
  3. Capacity utilisation: check commissioning of KAVACH 5-million-unit brownfield and 20-million-unit greenfield capacities against scheduled milestones.
  4. Customer qualification: check the Corning-linked venture for completed trials, volume orders, yields and actual collected revenue.
  5. CMF legal and commercial progress: confirm agreement, approvals, partnership economics and inventory responsibility.
  6. Cash and capital: reconcile capex, receivables, inventory, debt, finance cost and share issuance terms.
  7. Guidance versus delivery: test full-year FY27 revenue around ₹3,600 crore against actual H2 performance and retained EBITDA.
  8. Thesis breaker: sustained growth without improvement in cash return on capital and per-share economics would undermine the quality of the growth story.

Sources and methodology

Financial figures, new-venture plans and management targets are drawn from the issuer's revised Q2 FY27 investor presentation dated 6 November 2026 (). Results are corroborated against the NSE integrated filing dated 5 November 2026 (https://nsearchives.nseindia.com/corporate/ixbrl/INTEGRATED_FILING_INDAS_210590_05112026185745_iXBRL_WEB.html). Financial figures published in lakh are converted to crore. Management's adjusted profit and future guidance are labelled explicitly and are not treated as statutory earnings or research forecasts. A live price-based target and fully diluted fair value are not issued without corresponding dated inputs.

Additional company evidence

CHART 5

Management revenue objective

FY27₹3,600 crore
FY28₹6,500 crore
FY29₹8,500 crore

Optiemus revised issuer investor presentation dated 2026-11-06, Q2 FY27, consolidated financial summary

CHART 6

PAT margin

Q2 FY264.01%
Q1 FY272.4%
Q2 FY272.14%

Optiemus revised issuer investor presentation dated 2026-11-06, Q2 FY27, consolidated financial summary

CHART 7

Q2 reported versus adjusted EBITDA

Reported Q2₹40.14 crore
Issuer adjusted core Q2₹43.71 crore

Optiemus revised issuer investor presentation dated 2026-11-06, Q2 FY27, consolidated financial summary

SOURCE REFERENCES

Original disclosures and investor presentations

  1. Issuer disclosure

Related research and comparisons

Other published Q2 FY27 reports

This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.